Currently Viewing:
Newsroom
Currently Reading
Researchers Characterize Epidemiology of, Source of Infection in Febrile Neutropenia
February 16, 2019 – Jaime Rosenberg
Continuous Fingolimod Treatment Leads to 50% Reduction of ARRs
February 15, 2019 – Samantha DiGrande
CMS Proposes That Patients Be Enrolled in Studies to Get Coverage for CAR T-Cell Therapy
February 15, 2019 – Mary Caffrey and Allison Inserro
What We're Reading: Syphilis Rates Rising; House Democrats and ACA Suit; WHO to Look at Gene Editing
February 15, 2019 – AJMC Staff
HCCI Report: Healthcare Spending Increased Even as Utilization Decreased or Stagnated
February 15, 2019 – Wallace Stephens
AJMC® in the Press, February 15, 2019
February 15, 2019 – AJMC Staff
5 Findings From the February 2019 Issue of AJMC®
February 15, 2019 – Christina Mattina
This Week in Managed Care: February 15, 2019
February 15, 2019
Adding COPD Screenings to Drug Clinic Appointments Yields Benefits for Patients
February 15, 2019 – Allison Inserro

ICER to Review Five Biologic Drugs Used for Severe Asthma

Allison Inserro
The Institute for Clinical and Economic Review (ICER) is going to review the class of biologic drugs used to treat moderate to severe eosinophilic asthma and release a report in November, the organization said.
The Institute for Clinical and Economic Review (ICER) is going to review the class of biologic drugs used to treat moderate to severe eosinophilic asthma and release a report in November, the organization said. ICER performs analyses on the effectiveness and costs of medical tests, treatments, and delivery systems; develops reports assessing the value of key new drugs; and creates initiatives that use evidence to drive changes to both practice and policy. 

The asthma drugs are:
  • Dupilumab (Dupixent, Sanofi/Regeneron)
  • Omalizumab (Xolair, Genentech/Novartis),
  • Mepolizumab (Nucala, GlaxoSmithKline)
  • Reslizumab (Cinqair, Teva)
  • Benralizumab (Fasenra, AstraZeneca)
ICER previously reviewed mepolizumab for its use in severe eosinophilic asthma and dupilumab for its use in atopic dermatitis.

In its previous report on mepolizumab, ICER said the therapy should be priced far below its list price of $32,500 a year, suggesting that it would be cost effective if priced at no more than $7800 to about $12,000 a year.

Dupilumab is currently under FDA review for use as add-on maintenance treatment in moderate-to-severe asthma, with an approval decision expected in this October. It has “breakthrough” designation for its use in severe atopic dermatitis (AD) and is intended for patients whose condition has not improved with use of topical treatments, or who are not advised to take these treatments. Dupilumab works on 2 interleukins that are believed to trigger AD by binding to their cell receptors to calm the inflammatory response and reduce the symptoms.

Last year, ICER recommended that dupilumab represented a good value as it improved health outcomes even thought there were some additional costs.

Asthma costs the US economy more than $80 billion annually in medical expenses, days missed from work and school, and deaths, according to research published earlier this year in the Annals of the American Thoracic Society.

An estimated 22 million Americans have asthma, and the problem is going to get worse, with about 100 million people affected by 2025.

Related Articles

Dr Steve Pearson: Patient Perspectives Guide ICER Value Framework Development
Dr Steve Pearson Explains How ICER Price Benchmarks Align Cost With Patient Benefits
ICER Report: Despite High Price, Emicizumab for Hemophilia A Cuts Costs
ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit
ICER Study Compares Cost-Effectiveness of CGRP Inhibitors for Migraine
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!